tiamulin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibacterials, pleuromulin derivatives | 5628 | 55297-95-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Prevents senescence in ascomycete. pleuromutilin derivative
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| CHEBI has role | CHEBI:36047 | antibacterial drugs |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Swine | Swine pneumonia caused by Actinobacillus pleuropneumoniae | Indication |
| Swine | Swine dysentery associated with Treponema hyodysenteriae | Indication |
| Swine | Swine dysentery associated with Brachyspira (formerly Serpulina or Treponemahyodysenteriae) | Indication |
| Swine | Proliferative enteropathies (ileitis) associated with Lawsonia intracellularis | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Denagard Soluble Antibiotic | Elanco US Inc. | 1 |
| Denagard 10, Denagard 80% Coated | Elanco US Inc. | 1 |
| Denagard Liquid Concentrate | Elanco US Inc. | 1 |
| Denagard plus CTC | Elanco US Inc. | 2 |
| TiaGard, Tiamulin Soluble Antibiotic | Phibro Animal Health Corp. | 1 |
| Pennchlor / Denagard | Pharmgate Inc. | 2 |
| Tiagard, Tiamulin Liquid Concentrate | Elanco US Inc. | 1 |
| Triamulox | Zoetis Inc. | 1 |
| BimaGard 12.5% | Bimeda Animal Health Limited | 1 |
| Denagard and Deracin | Pharmgate Inc. | 2 |
| Vetmulin 12.5% | Huvepharma EOOD | 1 |
| TIA 12.5% | Virbac AH Inc. | 1 |
| TiaGard 12.5% | Aurora Pharmaceutical Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Cytochrome P450 3A4 | Enzyme | IC50 | 5.80 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| CHEBI:44137 | CHEBI |
| MUL | PDB_CHEM_ID |
| CHEMBL1234521 | ChEMBL_ID |
| CHEMBL498466 | ChEMBL_ID |
| C014224 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB11468 | DRUGBANK_ID |
| C0076651 | UMLSCUI |
| CHEMBL2146129 | ChEMBL_ID |
| 3932 | INN_ID |
| 373552001 | SNOMEDCT_US |
| 96018008 | SNOMEDCT_US |
| D06127 | KEGG_DRUG |
| 656958 | PUBCHEM_CID |
| 1546410 | RXNORM |
| E38WZ4U54R | UNII |
Pharmaceutical products:
None